Eisai gets FDA orphan drug designation for lymphoma drug; Berg, DOD partner on prostate cancer research;

@FierceBiotech: Popular yesterday: Upsized Intrexon IPO delivers another blockbuster success for billionaire Kirk. Story | Follow @FierceBiotech

@JohnCFierce: Over the past month 7 biotechs have raised $562M from IPOs. Brings the year's total so far to more than $2B. | Follow @JohnCFierce

@RyanMFierce: Ariad Pharma denied FDA's coveted 'breakthrough' stamp for lung cancer drug. News | Follow @RyanMFierce

@EmilyMFierce: NIH and Lacks family decision to open genomic data of HeLa cells to researchers will also establish genome database. Article | Follow @EmilyMFierce

> The FDA has granted orphan drug designation to Eisai's investigational compound, E7777, for cutaneous T-cell lymphoma. Release

> Keryx Biopharmaceuticals ($KERX) has submitted a New Drug Application (NDA) to the FDA, seeking approval for the marketing and sale of Zerenex for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease on dialysis. Release

> Biotech company Berg has partnered with the U.S. Department of Defense to find new biomarkers and investigate potential therapies for prostate cancer. Release

> Stem Cell Therapeutics has grabbed an option to license worldwide rights to prostate cancer stem cells from the U.K.'s University of York. Release

> Nature took a closer look at Cydan, a NEA- and Pfizer-backed vehicle, which the publication calls the first tech accelerator for rare disease therapies. Article

Medical Device News

@FierceMedDev: Zimmer owes Stryker $228M in patent lawsuit. News | Follow @FierceMedDev

@DamianFierce: Meet Verizon Wireless, medical device manufacturer. Story | Follow @DamianFierce

@MichaelGFierce: GE, U. of Wash. team up to make paper-based diagnostics device. Article | Follow @MichaelGFierce

> Alere wins FDA nod for HIV test, struggles on the Street. Report

> SightLine raises $107M fund for med tech investments. Item

Pharma News

@FiercePharma: Allergan joins the patent-loss party in India: Board revokes patents on Ganfort, Combigan glaucoma meds. Report | Follow @FiercePharma

@EricPFierce: Onyx CEO insists there are multiple players at buyout poker table. Reports had said Amgen sat alone. Story | Follow @EricPFierce

@CarlyHFierce: Incredulity turns to praise as malaria vax posts positive PhI data. More from FierceVaccines | Follow @CarlyHFierce

> Dendreon's Provenge sales off again, expected to miss for the year. More

> Pharma professionals feeling angst, but see a few rays of hope. Article

> Sun has terrific quarter, except for that Pfizer thing. Article

And Finally… An Xconomy contributor translates some biopharma industry jargon. Item

Suggested Articles

A patient has died in the global study of AstraZeneca’s COVID-19 vaccine, Brazil’s health authority, Anvisa, announced on Wednesday.

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.